drugset / Trial / NCT03727152
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir
Phase 3
Completed
170 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University · collabFaculty of Medical Sciences, Radboud University of Medical Center · collabPolice General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults
Timeline
- Start
- 2019-05-01
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Subject | tenofovir alafenamide | Small molecule | 25 mg | — |